European Primary Care Cardiovascular Society

COVID-19

Ongoing myocardial inflammation and cardiac involvement in recovered COVID-19 patients

Literature - July 30, 2020 - Puntmann VO et al., - JAMA Cardiol. 2020.

Cardiovascular MRI revealed cardiac involvement in 78% of patients and ongoing myocardial inflammation in 60% of patients in an unselected cohort of 100 patients who recently recovered from COVID-19.

Decrease in STEMI admissions reported by health professionals since COVID-19 outbreak

Literature - July 14, 2020 - Pessoa-Amorim G et al., - Eur Heart J Qual Care Clin Outcomes. 2020.

A survey conducted by the ESC among cardiologists and CV nurses revealed that 78.8% of responders perceived a decrease in STEMI admissions since the beginning of the COVID-19 outbreak.

More out-of-hospital cardiac arrest during COVID-19 outbreak in Lombardy, Italy

3' education - June 18, 2020 - Enrico Baldi, MD
There was a 58% increase in out-of-hospital cardiac arrest during the inital phase of the COVID-19 outbreak in the Lombardia region in Italy compared to the same period in 2019. Watch a video on the study by Baldi and colleagues.

Out-of-hospital cardiac arrest during the inital phase of the COVID-19 outbreak was substantially increased in the Lombardia region in Italy compared to the same period in 2019. Baldi briefly presents the details and outcomes of a study.

Issues of CV risk management in diabetes patients during the COVID-19 era

News - June 2, 2020

Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.

No harm of ARBs/ACEi in COVID-19 patients, demonstrated in three studies

News - June 2, 2020
Recently, three papers were published in the N Engl J Med on the effect of ACE inhibitors and (ARBs in patients with COVID-19, which all three showed no evidence that ACE inhibitors or ARBs affect the risk of COVID-19

Recently, three papers were published in the N Engl J Med on the effect of ACE inhibitors and (ARBs in patients with COVID-19, which all three showed no evidence that ACE inhibitors or ARBs affect the risk of COVID-19

High incidence of acute kidney injury in COVID-19 patients

Literature - May 28, 2020 - Hirsch JS et al., - Kidney Int. 2020.

This study showed that 36.3% of patients hospitalized with COVID-19 developed acute kidney injury during hospitalization.

Coagulopathy in COVID-19

Literature - May 28, 2020 - Levi M et al., - Lancet Haematol. 2020.

This comment article describes characteristics of coagulopathy in patients with COVID-19 and discusses recommendations for the therapeutic management of COVID-19-associated coagulopathy.

Management of diabetes during COVID-19 pandemic - practical recommendations

News - May 19, 2020

A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.

Hospitalized COVID-19 patients have a high risk of VTE

Literature - May 14, 2020 - Middeldorp S et al., - J Thromb Haemost 2020

Cumulative incidences of diagnosed and symptomatic VTE are increased in COVID-19 patients hospitalized in a Dutch hospital, with higher risk in those admitted to the ICU as compared to the general ward.

In ICU patients with COVID-19 pneumonia incidence of thrombotic complications is high

Literature - May 14, 2020 - Klok FA et al. - Thrombosis Research 2020
This observational study in 184 patients with COVID-19 pneumonia admitted to the ICU in the Netherlands showed a cumulative incidence of venous thromboembolism and arterial thrombotic complications of 31%.

This observational study in 184 patients with COVID-19 pneumonia admitted to the ICU in the Netherlands showed a cumulative incidence of venous thromboembolism and arterial thrombotic complications of 31%.

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - May 14, 2020 - Prof. Jan Danser, PhD
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focuses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.

This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focuses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.

COVID-19, ACE2 and RAASi - a clinical perspective

10' education - May 14, 2020 - Prof. Murray Epstein, MD
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents what the clinical implications are of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents what the clinical implications are of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

COVID-19